Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares

Nkarta, Inc. (NASDAQ:NKTX) President Nadir Mahmood sold 5,649 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total transaction of $11,693.43. Following the completion of the sale, the president owned 167,727 shares in the company, valued at $347,194.89. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nkarta Stock Performance

NKTX remained flat at $2.04 during trading on Tuesday. The company had a trading volume of 357,832 shares, compared to its average volume of 794,083. The firm has a market capitalization of $144.90 million, a P/E ratio of -1.48 and a beta of 0.60. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $2.74. The company has a 50-day moving average of $1.88 and a 200-day moving average of $2.03.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.03. Analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on NKTX shares. Stifel Nicolaus cut their price target on Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Forefront Analytics LLC lifted its holdings in shares of Nkarta by 41.0% during the 3rd quarter. Forefront Analytics LLC now owns 39,452 shares of the company’s stock valued at $82,000 after purchasing an additional 11,473 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in shares of Nkarta in the third quarter valued at approximately $90,000. Millennium Management LLC bought a new stake in Nkarta during the 3rd quarter worth about $1,549,000. Virtu Financial LLC bought a new stake in Nkarta during the third quarter worth about $102,000. Finally, Man Group plc bought a new position in Nkarta in the third quarter valued at approximately $90,000. Institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.